| __timestamp | Axsome Therapeutics, Inc. | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 1802274 |
| Thursday, January 1, 2015 | 2419289 | 2512761 |
| Friday, January 1, 2016 | 6343648 | 2894488 |
| Sunday, January 1, 2017 | 7206691 | 8096274 |
| Monday, January 1, 2018 | 9351522 | 7985229 |
| Tuesday, January 1, 2019 | 13598030 | 8994597 |
| Wednesday, January 1, 2020 | 28896749 | 29772000 |
| Friday, January 1, 2021 | 66646205 | 33907000 |
| Saturday, January 1, 2022 | 159253661 | 26579000 |
| Sunday, January 1, 2023 | 323123000 | 49868547 |
| Monday, January 1, 2024 | 411359000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. From 2014 to 2023, Axsome Therapeutics, Inc. and Verona Pharma plc have shown distinct strategies in handling these costs. Axsome's SG&A expenses surged by over 23,000% from 2014 to 2023, reflecting aggressive expansion and investment in growth. In contrast, Verona Pharma maintained a more conservative approach, with a 2,700% increase over the same period. Notably, in 2023, Axsome's SG&A expenses were approximately 6.5 times higher than Verona's, indicating a significant divergence in financial strategy. This data highlights the contrasting paths these companies have taken in their quest for market leadership. Understanding these trends provides valuable insights into their operational priorities and future trajectories.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Verona Pharma plc
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Axsome Therapeutics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Verona Pharma plc or MorphoSys AG
Who Optimizes SG&A Costs Better? Verona Pharma plc or Supernus Pharmaceuticals, Inc.